Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus GG + Bifidobacterium animalis subsp. lactis BB-12 (Medical University of Warsaw)
- Development stage
- Discontinued
- Lead developer
- Novonesis
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus GG + Bifidobacterium animalis subsp. lactis BB-12 is an investigational combination of two live probiotic bacterial strains. It was studied by the Medical University of Warsaw in the NCT03032354 clinical trial, a randomized, double-blind, placebo-controlled study in children with newly diagnosed type 1 diabetes mellitus. [1, 7] The intervention aimed to preserve residual pancreatic beta-cell function by modulating the gut microbiota to influence the immune system and prevent further islet cell destruction. [4] The trial results, published in 2021, showed that the probiotic combination did not have a significant effect on maintaining beta-cell function compared to placebo. [2, 3]
- Other names
- LGG and BB-12 in newly diagnosed type 1 diabetesLactobacillus rhamnosus GG and Bifidobacterium lactis BB12
02
Targets
Beyond the preview
Go deeper on Lactobacillus rhamnosus GG + Bifidobacterium animalis subsp. lactis BB-12 (Medical University of Warsaw).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus GG + Bifidobacterium animalis subsp. lactis BB-12 (Medical University of Warsaw).